NXTC NextCure, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

NXTC [NASD]

NextCure, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	13.53%	Shs Outstand	27.51M	Perf Week	-22.18%
Market Cap	786.78M	Forward P/E	-	EPS next Y	-2.52	Insider Trans	0.00%	Shs Float	23.79M	Perf Month	-23.24%
Income	-17.80M	PEG	-	EPS next Q	-0.50	Inst Own	81.70%	Short Float	5.03%	Perf Quarter	-38.11%
Sales	27.40M	P/S	28.71	EPS this Y	-106.80%	Inst Trans	0.52%	Short Ratio	4.86	Perf Half Y	-38.33%
Book/sh	12.06	P/B	2.23	EPS next Y	-21.80%	ROA	-6.40%	Target Price	-	Perf Year	51.78%
Cash/sh	11.00	P/C	2.44	EPS next 5Y	28.20%	ROE	-7.10%	52W Range	13.86 - 109.00	Perf YTD	-52.28%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-11.50%	52W High	-75.34%	Beta	-
Dividend %	-	Quick Ratio	40.10	Sales past 5Y	-	Gross Margin	-	52W Low	93.94%	ATR	2.70
Employees	69	Current Ratio	40.10	Sales Q/Q	1549.10%	Oper. Margin	-81.90%	RSI (14)	33.53	Volatility	9.41% 8.23%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	218.20%	Profit Margin	-65.20%	Rel Volume	1.96	Prev Close	28.69
Shortable	No	LT Debt/Eq	0.01	Earnings	Mar 17	Payout	-	Avg Volume	246.42K	Price	26.88
Recom	1.70	SMA20	-21.10%	SMA50	-23.34%	SMA200	-32.93%	Volume	483,327	Change	-6.31%

Jun-01-20

Downgrade

The Benchmark Company

Buy → Hold

Jun-01-20

Downgrade

BofA/Merrill

Buy → Neutral

$62 → $40

May-26-20

Initiated

JMP Securities

Mkt Outperform

$55

Mar-24-20

Initiated

The Benchmark Company

Buy

$55

Mar-02-20

Initiated

ROTH Capital

Buy

$80

Jan-13-20

Initiated

SunTrust

Buy

$78

Dec-05-19

Initiated

Needham

Buy

Nov-26-19

Initiated

BTIG Research

Buy

$61

Jul-09-19

Initiated

BofA/Merrill

Buy

$25

Jun-03-19

Initiated

Piper Jaffray

Overweight

$26

Jun-03-19

Initiated

Morgan Stanley

Overweight

$25

May-29-20 08:05AM	NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting GlobeNewswire -5.99%
May-28-20 02:55PM	7 High-Risk Stocks For Market Gamblers Benzinga
May-07-20 06:45PM	NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates Zacks +6.06%
05:10PM	NextCure Reports First Quarter 2020 Financial Results GlobeNewswire
May-06-20 08:05AM	NextCure to Present at BofA Securities Virtual Health Care Conference GlobeNewswire
Apr-15-20 12:28PM	Hedge Funds Have Never Been This Bullish On NextCure, Inc. (NXTC) Insider Monkey -8.64%
Apr-13-20 07:05AM	NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic GlobeNewswire -10.42%
Apr-08-20 07:05AM	NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire +7.20%
Mar-30-20 07:05AM	NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors GlobeNewswire
Mar-26-20 08:52AM	Why You Shouldn't Bet Against NextCure (NXTC) Stock Zacks +10.25%
Mar-12-20 05:00PM	NextCure Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire -14.34%
Feb-25-20 08:05AM	NextCure to Present at the 40th Annual Cowen Health Care Conference GlobeNewswire -7.22%
Feb-18-20 08:05AM	NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-14-20 03:12PM	Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech American City Business Journals
Jan-06-20 04:10PM	NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-19 05:05AM	3 Healthcare Stocks With 100% Street Support TipRanks
Dec-16-19 06:11AM	Is NextCure, Inc. (NXTC) A Good Stock To Buy ? Insider Monkey
Nov-26-19 08:05AM	NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-19-19 04:05PM	NextCure Announces Closing of Public Offering GlobeNewswire
Nov-15-19 10:09AM	The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga -6.49%
Nov-14-19 10:10PM	NextCure Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-12-19 04:18PM	NextCure Announces Proposed Public Offering of Common Stock GlobeNewswire
03:25PM	Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside Benzinga
08:05AM	NextCure Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-11-19 01:37PM	NextCure Stock Collapses After New Cancer Drug Data Barrons.com -52.93%
10:53AM	These Are The Winners Of The Inaugural WeTrader Paper Trading Competition Benzinga
Nov-09-19 05:05PM	NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial GlobeNewswire
Nov-04-19 08:05AM	NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-01-19 04:24PM	WeWork IPO was a Failure These 2 IPO Stocks are Surging InvestorPlace +9.40%
Oct-02-19 07:30AM	NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer GlobeNewswire
Oct-01-19 06:20PM	NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC GlobeNewswire
Sep-03-19 04:05PM	NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire +6.02%
Aug-12-19 04:05PM	NextCure Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-08-19 06:02AM	What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock? Simply Wall St. -6.68%
Jul-18-19 11:20AM	2 Small-Cap Biotech IPOs You Should Know About Motley Fool +6.36%
Jun-10-19 04:05PM	NextCure Reports First Quarter 2019 Financial Results GlobeNewswire -5.67%
May-08-19 08:46PM	NextCure Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
May-04-19 05:25PM	IPO Outlook For The Week: Uber (And 11 Others) Benzinga

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Liu Linda	SVP, Research	Nov 27	Option Exercise	0.75	55,234	41,656	55,234	Feb 21 04:11 PM
Sofinnova Venture Partners IX,	10% Owner	Nov 15	Buy	36.75	150,000	5,512,500	2,671,856	Nov 19 09:47 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience